April 7, 2022 / 5:30-7:30pm PT
Join us at ASBrS 2022 for a symposium
Personalizing Care for Early Breast Cancer Patients: TAILORx, RxPONDER, and Beyond
Dr. Christy Russell (Vice President, US Medical Affairs at Exact Sciences) will lead a discussion with exploring how the Oncotype DX Breast Recurrence Score®
test can help inform systemic therapy decisions for early node-negative and node-positive breast cancer patients. She will also explore ongoing studies on gene signatures that may help personalize radiotherapy decisions in early breast cancer.
Christy Russell, MD
Vice President, US Medical Affairs at Exact Sciences
Corey Speers, MD, PhD
Associate Professor of Radiation Oncology, University of Michigan Medical School
Jennifer Racz, MD, MBA
Associate Professor, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health
1. Iwata H, et al. Breast Cancer Res Treat. 2019.